Document Detail


ACE I/D and ACTN3 R/X polymorphisms as potential factors in modulating exercise-related phenotypes in older women in response to a muscle power training stimuli.
MedLine Citation:
PMID:  22855367     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Genetic variation of the human ACE I/D and ACTN3 R577X polymorphisms subsequent to 12 weeks of high-speed power training on maximal strength (1RM) of the arm and leg muscles, muscle power performance (counter-movement jump), and functional capacity (sit-to-stand test) was examined in older Caucasian women [n = 139; mean age 65.5 (8.2) years; 67.0 (10.0) kg and 1.57 (0.06) m]. Chelex 100 was used for DNA extraction, and genotype was determined by PCR-RFLP methods. Muscular strength, power, and functional testing were conducted at baseline (T1) and after 12 weeks (T2) of high-speed power training. At baseline, the ACE I/D and ACTN3 R/X polymorphisms were not associated with muscle function or muscularity phenotypes in older Caucasian women. After the 12-week high-speed training program, subjects significantly increased their muscular and functional capacity performance (p < 0.05). For both polymorphisms, significant genotype-training interaction (p < 0.05) was found in all muscular performance indices, except for 1RM leg extension in the ACE I/D (p = 0.187). Analyses of the combined effects between genotypes showed significant differences in all parameters (p < 0.05) in response to high-speed power training between the power (ACTN3 RR + RX & ACE DD) versus "non-power" muscularity-oriented genotypes (ACTN3 XX & ACE II + ID)]. Our data suggest that the ACE and ACTN3 genotypes (single or combined) exert a significant influence in the muscle phenotypes of older Caucasian women in response to high-speed power training. Thus, the ACE I/D and ACTN3 R/X polymorphisms are likely factors in modulating exercise-related phenotypes in older women, particularly in response to a resistance training stimuli.
Authors:
Ana Pereira; Aldo M Costa; Mikel Izquierdo; António J Silva; Estela Bastos; Mário C Marques
Related Documents :
7677677 - The biochemistry and clinical application of urinary oestriol measurement during late p...
17253077 - The colpexin sphere: a new conservative management option for pelvic organ prolapse.
24112827 - Acute molecular responses in untrained and trained muscle subjected to aerobic and resi...
1988637 - Quantification of hepatobiliary function as an integral part of imaging with technetium...
24431957 - The impact of ergometer design on hip and trunk muscle activity patterns in elite rower...
10195327 - Metabolite changes in neonatal rat brain during and after cerebral hypoxia-ischemia: a ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-02
Journal Detail:
Title:  Age (Dordrecht, Netherlands)     Volume:  35     ISSN:  1574-4647     ISO Abbreviation:  Age (Dordr)     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-09-18     Completed Date:  2014-05-20     Revised Date:  2014-10-15    
Medline Journal Info:
Nlm Unique ID:  101250497     Medline TA:  Age (Dordr)     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1949-59     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Actinin / genetics*,  metabolism
Aged
Aging / genetics*
DNA / genetics
Exercise / physiology*
Female
Follow-Up Studies
Genotype
Humans
Muscle Contraction / physiology
Muscle Strength / genetics*
Peptidyl-Dipeptidase A / genetics*,  metabolism
Phenotype
Polymerase Chain Reaction
Polymorphism, Genetic*
Resistance Training / methods*
Chemical
Reg. No./Substance:
0/ACTN3 protein, human; 11003-00-2/Actinin; 9007-49-2/DNA; EC 3.4.15.1/Peptidyl-Dipeptidase A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Periodontal infections and community-acquired pneumonia: a case-control study.
Next Document:  Statistical considerations when using a composite endpoint for comparing treatment groups.